The capsid revolution  

作　　者：Ian A.Taylor Ariberto Fassati 

机构地区：[1]Macromolecular Structure Laboratory,The Francis Crick Institute,London NW11AT,UK [2]Division of Infection and Immunity,University College London,London WC1E 6JF,UK [3]Institute of Immunity and Transplantation,University College London,London NW32PP,UK

出　　处：《Journal of Molecular Cell Biology》2023年第11期1-11,共11页分子细胞生物学报（英文版）

基　　金：supported by the UK Medical Research Council(MR/W001241/1 to A.F.);the Canadian Institute of Health Research(PJT-178127 to A.F.);the Francis Crick Institute(to I.A.T.),with core funding from Cancer Research UK(CC2029);the UK Medical Research Council(CC2029);the Wellcome Trust(CC2029).

摘　　要：Lenacapavir,targeting the human immunodeficiency virus type-1(HIV-1)capsid,is the first-in-class antiretroviral drug recently approved for clinical use.The development of Lenacapavir is attributed to the remarkable progress in our understanding of the capsid protein made during the last few years.Considered little more than a component of the virus shell to be shed early during infection,the capsid has been found to be a key player in the HIV-1 life cycle by interacting with multiple host factors,entering the nucleus,and directing integration.Here,we describe the key advances that led to this‘capsid revolution’.

关 键 词：HIV-1 capsid CPSF6 Lenacapavir INTEGRATION IP6 NUCLEUS reverse transcription 

分 类 号：R512.91[医药卫生—内科学]